Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name	MAP2K1 K57N
Gene Variant Detail	MAP2K1 K57N (gain of function)
Relevant Treatment Approaches	MEK inhibitor (Pan) MEK1 Inhibitor

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 18 of 18 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
MAP2K1 K57N	lymphatic system cancer	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with refractory Erdheim-Chester disease harboring a MAP2K1 K57N mutation had a sustained clinical response to Mekinist (trametinib) for over 6 months (PMID: 26566875).	26566875
MAP2K1 K57N	lung non-squamous non-small cell carcinoma	predicted - sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Trametinib	Case Reports/Case Series	Actionable	In a clinical case study, Mekinist (trametinib) treatment resulted in a radiographic response with a decrease in the size of multiple metastatic sites in a patient with non-squamous non-small cell lung cancer harboring MAP2K1 K57N (PMID: 36455195).	36455195
MAP2K1 K57N	colorectal cancer	resistant		Panitumumab	Case Reports/Case Series	Actionable	In a retrospective analysis, two patients with metastatic RAS/BRAF wild-type colorectal cancer demonstrated progressive disease following treatment with Vectibix (panitumumab) and via analysis of archived pretreatment tumor biopsy samples and post-progression liquid biopsy both were found to harbor MAP2K1 K57N (PMID: 36419886).	36419886
MAP2K1 K57N	lung adenocarcinoma	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Koselugo (selumetinib) inhibited phosphorylation of ERK in cells expressing MAP2K1 K57N and inhibited MAP2K1 K57N-dependent growth in cell culture (PMID: 18632602).	18632602
MAP2K1 K57N	Advanced Solid Tumor	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed sensitivity to the Mek inhibitor, Selumetinib (AZD6244), as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 K57N	Advanced Solid Tumor	sensitive		PLX4720	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed sensitivity to the Braf inhibitor, PLX4720, as demonstrated by reversal of active Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 K57N	Advanced Solid Tumor	resistant	MEK1 Inhibitor	PD98059	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed resistance to the Mek inhibitor, PD98059, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 K57N	Advanced Solid Tumor	resistant		Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed resistance to Stivarga (regorafenib; BAY 73-4506), as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 K57N	Advanced Solid Tumor	resistant		GDC0879	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed resistance to the Braf inhibitor, GDC-0879, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 K57N	Advanced Solid Tumor	resistant	MEK inhibitor (Pan) MEK1 Inhibitor	AZD8330	Preclinical - Cell culture	Actionable	In a preclinical study, Map2k1 K57N displayed resistance to the Mek inhibitor, AZD8330, as demonstrated by constitutive activation of Map2k1 in transformed human kidney cells (PMID: 29753091).	29753091
MAP2K1 K57N	Advanced Solid Tumor	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Koselugo (selumetinib) inhibited colony formation of transformed cells expressing MAP2K1 K57N in culture (PMID: 25351745).	25351745
MAP2K1 K57N	Advanced Solid Tumor	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 K57N in culture (PMID: 36442478).	36442478
MAP2K1 K57N	Advanced Solid Tumor	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Trametinib	Preclinical - Biochemical	Actionable	In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation in transformed cells expressing MAP2K1 K57N in culture (PMID: 32641410).	32641410
MAP2K1 K57N	Advanced Solid Tumor	predicted - sensitive		SCH772984	Preclinical - Biochemical	Actionable	In a preclinical study, SCH772984 inhibited downstream signaling in transformed cells expressing MAP2K1 K57N in culture (PMID: 32641410).	32641410
MAP2K1 K57N	colorectal cancer	resistant		Cetuximab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Erbitux (cetuximab) in culture (PMID: 26644315).	26644315
MAP2K1 K57N	colorectal cancer	resistant		Panitumumab	Preclinical	Actionable	In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Vectibix (panitumumab) in culture (PMID: 26644315).	26644315
MAP2K1 K57N	colorectal cancer	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Cetuximab + Trametinib	Preclinical	Actionable	In a preclinical study, Erbitux (cetuximab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57N in culture (PMID: 26644315).	26644315
MAP2K1 K57N	colorectal cancer	sensitive	MEK inhibitor (Pan) MEK1 Inhibitor	Panitumumab + Trametinib	Preclinical	Actionable	In a preclinical study, Vectibix (panitumumab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57N in culture (PMID: 26644315).	26644315

Showing 1 to 18 of 18 entries

Filter rows: